UNCYHIGH SIGNALREGULATORY10-K

The FDA issued a Complete Response Letter (CRL) for Unicycive's lead drug OLC in June 2025 due to a third-party manufacturing vendor deficiency, materially delaying potential approval and commercial launch.

The CRL represents a critical setback for UNCY, a pre-commercial clinical-stage company whose entire near-term value thesis rested on OLC approval by the June 28, 2025 PDUFA date. While the deficiency appears narrowly scoped to a single third-party CDMO vendor — and a Type A meeting was held with the FDA in October 2025 to discuss resolution — the timeline to resubmission and potential re-review remains uncertain, extending the company's cash burn period without revenue. Investors should closely monitor the resubmission timeline and any further FDA correspondence, as this regulatory overhang is the dominant risk to equity value.

Comparing 2026-03-30 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

The balance sheet improved meaningfully, with current assets growing substantially to $49.0M (up 58.2%) and total liabilities declining to $18.9M (down 21.9%), suggesting a capital raise or cash infusion that extended the company's runway — critical context given the regulatory delay. R&D expense declined meaningfully year-over-year to $9.1M from $20.0M, likely reflecting the wind-down of late-stage clinical spending as OLC approached its PDUFA date, while revenue declined modestly to $675K from $951K. Net loss narrowed to $26.6M from $36.7M, consistent with the lower R&D spend, but the overall picture signals a company in a holding pattern — conserving cash while navigating a regulatory resolution that will ultimately determine whether the improved balance sheet is sufficient to reach commercialization.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-66.7%
$72K→$24K

Capex reduced 66.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Current Assets
Balance Sheet
+58.2%
$30.9M→$49.0M

Current assets grew 58.2% — improving short-term liquidity or inventory/receivables build.

SG&A Expense
P&L
+56.3%
$245K→$383K

SG&A up 56.3% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Total Assets
Balance Sheet
+55.2%
$31.7M→$49.1M

Asset base grew 55.2% — expansion through organic growth, acquisitions, or capital deployment.

R&D Expense
P&L
-54.4%
$20.0M→$9.1M

R&D spending cut 54.4% — could signal cost discipline or concerning reduction in innovation investment.

Revenue
P&L
-29%
$951K→$675K

Revenue softened 29% — monitor whether this is cyclical or structural.

Net Income
P&L
+27.7%
-$36.7M→-$26.6M

Net income grew 27.7% — bottom-line growth signals improving overall business health.

Total Liabilities
Balance Sheet
-21.9%
$24.2M→$18.9M

Liabilities reduced 21.9% — deleveraging improves balance sheet strength and financial flexibility.

Dividends Paid
Cash Flow
+21.7%
$900K→$1.1M

Dividend payments increased 21.7% — management confidence in sustained cash generation.

Current Liabilities
Balance Sheet
-21.5%
$24.1M→$18.9M

Current liabilities reduced — improved short-term financial position and working capital health.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-03-31
ADDED
You may experience dilution, subordination of stockholder rights, preferences, and privileges, and decrease in market price of our common stock as a result of our private placement in March 2023.
We do not intend to pay cash dividends on our shares of common stock so any returns will be limited to the value of our shares, except we have agreed to pay cash dividends in the event oxylanthanum carbonate is approved by the FDA and commercial sales is commenced - iv - PART I Throughout this Annual Report on Form 10-K, references to we, our, us, the Company, Unicycive, or Unicycive Therapeutics refer to Unicycive Therapeutics, Inc.
In September 2024, we submitted a New Drug Application (NDA) for OLC to the FDA.
In November 2024 we announced the FDA had accepted its NDA and set a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2025.
In June 2025, the FDA issued us a Complete Response Letter (CRL) notifying us that a third-party manufacturing vendor of its main contract development and manufacturing organization (CDMO) was cited for deficiencies following a cGMP inspection.
In October 2025, we held a Type A meeting with the FDA to discuss the resolution of the single deficiency identified in the CRL related to the compliance status of a third-party manufacturing vendor.
Following receipt of the official meeting minutes from the Type A meeting and engaging in discussions with its third-party manufacturing vendor, we resubmitted its NDA to the FDA in December 2025.
In January 2026, the FDA accepted the resubmission of the NDA for OLC, deeming the resubmission to be a Class II complete response which has a six-month review period from the date of resubmission, and set a PDUFA) target action date of June 29, 2026.
Figure 11: Summary of Mean Change in Urinary Phosphorus Excretion (mg/day) Regulatory Guidance We are seeking approval for oxylanthanum carbonate from the U.S.
In June 2025 the FDA issued us a Complete Response Letter (CRL) notifying us that a third-party manufacturing vendor of its main contract development and manufacturing organization (CDMO) was cited for deficiencies following a cGMP inspection.
REMOVED
You may experience dilution, subordination of stockholder rights, preferences, and privileges, and decrease in market price of our common stock as a result of our private placements in March 2023 and March 2024.
We do not intend to pay cash dividends on our shares of common stock so any returns will be limited to the value of our shares, except we have agreed to pay cash dividends in the event ( Oxylanthanum Carbonate ) is approved by the FDA and commercial sales is commenced.
- iv - PART I Throughout this Annual Report on Form 10-K, references to we, our, us, the Company, Unicycive, or Unicycive Therapeutics refer to Unicycive Therapeutics, Inc.
The Company has submitted a New Drug Application (NDA) and has an assigned Prescription Drug User Fee Act (PDUFA) date of June 28, 2025.
Hyperphosphatemia is also a major cause of morbidity in CKD patients, which increases the economic and clinical burden on patients and the health system and results in Medicare expenditures of $70 billion in the U.S.
Figure 11: Summary of Mean Change in Urinary Phosphorus Excretion (mg/day) Regulatory Guidance Unicycive is seeking approval for Oxylanthanum Carbonate from the U.S.
In March 2025, FDA conducted a general surveillance inspection of Shilpa Medicare Ltd, where the company received one procedural observation in form 483.
Current phosphate binder products such as Renvela , Calcium Acetate, Auryxia , Velphoro , and Fosrenol involve patients needing to take large numbers and/or large sized pills each day which in some cases must be chewed and which often results in poor adherence to the prescribed drug therapy ( Figure 12 ).
Figure 12: Recommended Daily Starting Dose for Phosphate Binders Tenapanor (Ardelyx): A New Hyperphosphatemia Market Player Tenapanor is a new oral treatment for hyperphosphatemia that utilizes a novel mechanism of action that inhibits paracellular transport of phosphorus into the bloodstream.We believe that due to its novel mechanism of action, Xphozah represents an important new addition to the nephrologist s hyperphosphatemia treatment armamentarium.
One of the key features of Xphozah s value proposition as an add-on therapy is its low pill burden.
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →